💊 AbbVie beats expectations: shares rise thanks to strong results and optimistic outlook! 🚀

Shares of biotech giant AbbVie $ABBV are up more than 4 %, after announcing better-than-expected quarterly earnings while raising its long-term outlook. Sales of Skyrizi and Rinvoq were a key driver of growth , offsetting declines in the once-flagship drug Humira.

📊 Q4 key numbers

Sales: $15.1 billion (vs. expectations of $14.8 billion)

Year-over-year revenue growth: +5,6 %

Earnings per share (EPS): $2.16 (fell slightly short of estimates of $2.18)

💡 Key growth drivers:

Skyrizi (autoimmune treatment): +58%, sales reached $3.78 billion

Rinvoq (rheumatology and immunology): +46%, sales of USD 1.83 billion

Neurosciences (Vraylar): +19.8%, total sales of USD 2.5 billion

Oncology Division: Revenue grew 12.9%, with Venclexta adding +13%

📉 Conversely, Humira'ssales declined by 49 % to $1.68 billion due to loss of exclusivity and increasing competition from biosimilars.

🔮 Optimistic outlook for 2027 and beyond
AbbVie raised its long-term outlook for key products:

Skyrizi + Rinvoq: Combined revenues expected to exceed $31 billion in 2027 (original estimate $27 billion)

Skyrizi: More than USD 20 billion

Rinvoq: More than USD 11 billion

Aesthetic Medicine (Botox, Juvederm): Expects steady single-digit growth through 2029

In addition, the company confirmed its expectation of high single-digit growth in total revenue through 2029.

📈 Interesting for investors
Strong position in autoimmune drugs - Skyrizi and Rinvoq are emerging as full-fledged successors to Humira.
Neuroscience and oncology segments are high-margin, long-term demand segments.
Strong cash flow and dividend stability - AbbVie is one of the top dividend paying stocks in the S&P 500.

What do you think of this company?